A citation-based method for searching scientific literature

Erin E Mulvihill, Daniel J Drucker. Endocr Rev 2014
Times Cited: 291







List of co-cited articles
817 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, Mark E Cooper, Steven E Kahn, Nikolaus Marx, John H Alexander, Michael Pencina, Robert D Toto, Christoph Wanner,[...]. JAMA 2019
448
15

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
14

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
C Klemann, L Wagner, M Stephan, S von Hörsten. Clin Exp Immunol 2016
187
13

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
628
13

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
13

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
759
12

Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition.
Elodie M Varin, Erin E Mulvihill, Jacqueline L Beaudry, Gemma Pujadas, Shai Fuchs, Jean-François Tanti, Sofia Fazio, Kirandeep Kaur, Xiemin Cao, Laurie L Baggio,[...]. Cell Metab 2019
57
19


Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
11

DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
188
10

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10

Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study.
Sebastiano Bruno Solerte, Francesca D'Addio, Roberto Trevisan, Elisabetta Lovati, Antonio Rossi, Ida Pastore, Marco Dell'Acqua, Elio Ippolito, Cristiana Scaranna, Rosalia Bellante,[...]. Diabetes Care 2020
103
10

Cellular Sites and Mechanisms Linking Reduction of Dipeptidyl Peptidase-4 Activity to Control of Incretin Hormone Action and Glucose Homeostasis.
Erin E Mulvihill, Elodie M Varin, Bojana Gladanac, Jonathan E Campbell, John R Ussher, Laurie L Baggio, Bernardo Yusta, Jennifer Ayala, Melissa A Burmeister, Dianne Matthews,[...]. Cell Metab 2017
59
15



Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
8

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
8

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D Margriet Ouwens, Kristin Eckardt, Jean M Kaufman, Mikael Ryden, Stefan Müller,[...]. Diabetes 2011
384
8


Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC.
V Stalin Raj, Huihui Mou, Saskia L Smits, Dick H W Dekkers, Marcel A Müller, Ronald Dijkman, Doreen Muth, Jeroen A A Demmers, Ali Zaki, Ron A M Fouchier,[...]. Nature 2013
8

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Markus Hoffmann, Hannah Kleine-Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S Schiergens, Georg Herrler, Nai-Huei Wu, Andreas Nitsche,[...]. Cell 2020
8

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
D Marguet, L Baggio, T Kobayashi, A M Bernard, M Pierres, P F Nielsen, U Ribel, T Watanabe, D J Drucker, N Wagtmann. Proc Natl Acad Sci U S A 2000
408
7

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
7

Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Michael A Nauck, Juris J Meier, Matthew A Cavender, Mirna Abd El Aziz, Daniel J Drucker. Circulation 2017
233
7

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
7

Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy.
Marco Mirani, Giuseppe Favacchio, Flaminia Carrone, Nazarena Betella, Emilia Biamonte, Emanuela Morenghi, Gherardo Mazziotti, Andrea Gerardo Lania. Diabetes Care 2020
58
12

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.
Devram S Ghorpade, Lale Ozcan, Ze Zheng, Sarah M Nicoloro, Yuefei Shen, Emily Chen, Matthias Blüher, Michael P Czech, Ira Tabas. Nature 2018
117
6



Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
6

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
6

Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
256
6

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
Julio Rosenstock, Steven E Kahn, Odd Erik Johansen, Bernard Zinman, Mark A Espeland, Hans J Woerle, Egon Pfarr, Annett Keller, Michaela Mattheus, David Baanstra,[...]. JAMA 2019
193
6

β Cell tone is defined by proglucagon peptides through cAMP signaling.
Megan E Capozzi, Berit Svendsen, Sara E Encisco, Sophie L Lewandowski, Mackenzie D Martin, Haopeng Lin, Justin L Jaffe, Reilly W Coch, Jonathan M Haldeman, Patrick E MacDonald,[...]. JCI Insight 2019
79
7

Clinical Use of DPP-4 Inhibitors.
Baptist Gallwitz. Front Endocrinol (Lausanne) 2019
64
9

Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection.
Kirsten A Kulcsar, Christopher M Coleman, Sarah E Beck, Matthew B Frieman. JCI Insight 2019
159
6

The MERS-CoV Receptor DPP4 as a Candidate Binding Target of the SARS-CoV-2 Spike.
Yu Li, Ziding Zhang, Li Yang, Xianyi Lian, Yan Xie, Shen Li, Shuyu Xin, Pengfei Cao, Jianhong Lu. iScience 2020
84
7

Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase.
Marjolein J Willemen, Aukje K Mantel-Teeuwisse, Sabine M Straus, Ron H Meyboom, Toine C Egberts, Hubert G Leufkens. Diabetes Care 2011
89
5

Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4.
A Casrouge, A V Sauer, R Barreira da Silva, M Tejera-Alhambra, S Sánchez-Ramón, ICAReB, C Cancrini, M A Ingersoll, A Aiuti, M L Albert. Clin Exp Immunol 2018
25
20

On the origin of serum CD26 and its altered concentration in cancer patients.
Oscar J Cordero, Francisco J Salgado, Montserrat Nogueira. Cancer Immunol Immunother 2009
143
5


Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2016
62
8

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Keizo Kanasaki, Sen Shi, Megumi Kanasaki, Jianhua He, Takako Nagai, Yuka Nakamura, Yasuhito Ishigaki, Munehiro Kitada, Swayam Prakash Srivastava, Daisuke Koya. Diabetes 2014
224
5

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
Melanie J Davies, David A D'Alessio, Judith Fradkin, Walter N Kernan, Chantal Mathieu, Geltrude Mingrone, Peter Rossing, Apostolos Tsapas, Deborah J Wexler, John B Buse. Diabetes Care 2018
5

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.
Henrike Sell, Matthias Blüher, Nora Klöting, Raphaela Schlich, Miriam Willems, Florian Ruppe, Wolfram Trudo Knoefel, Arne Dietrich, Barbara A Fielding, Peter Arner,[...]. Diabetes Care 2013
136
5

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
5


Dipeptidylpeptidase 4 as a Marker of Activated Fibroblasts and a Potential Target for the Treatment of Fibrosis in Systemic Sclerosis.
Alina Soare, Hermina A Györfi, Alexandru E Matei, Clara Dees, Simon Rauber, Thomas Wohlfahrt, Chih-Wei Chen, Ingo Ludolph, Raymund E Horch, Tobias Bäuerle,[...]. Arthritis Rheumatol 2020
35
14


DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1/M2 Macrophage Polarization.
Fen Zhuge, Yinhua Ni, Mayumi Nagashimada, Naoto Nagata, Liang Xu, Naofumi Mukaida, Shuichi Kaneko, Tsuguhito Ota. Diabetes 2016
103
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.